The holy grail. How to stop #rheumatoid #arthritis in at risk Pts. Who to treat, when to stop? Many RCTs but no home run-NNT is high. #MTX and a diff study #Abatacept that work while on Rx and #Rituximab, most don’t work esp after stopping Rx @kevindeane #RNL23 ⁦@RheumNow⁩ https://t.co/BkIxxS0ecn

Dr. Deane's current management of "pre-RA" pts - carefully eval for synovitis - lifestyle factors - stop smoking, diet, dental hygiene - educate pt on ~30% risk - annual in-person follow up @RheumNow #RNL2023 https://t.co/Z0t0Yibyri

How do you prevent RA in at-risk patient? Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷 Education & follow-up! Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD #RNL2023 @RheumNow

Natural history of RA by Kevin Deane #RLN23 ⁦@RheumNow⁩ https://t.co/ab0cafDblz

The amazing JAKs The many JAK/TYK targets approved for multiple conditions Coming soon: UPA for Crohn's - first indication for Crohn's disease #RNL2023 @RheumNow https://t.co/Pf3gzrdyeq

Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/3ZZHr0akrR

JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 ⁦@RheumNow⁩ https://t.co/qBau79o0VQ

About to get my learnin' on! #RNL2023 @RheumNow

#RNL2023 is up and running! Join us online! @RheumNow https://t.co/AGbpEjXSh6

Follow me today and tomorrow for @RheumNow Live 2023 Coverage! #RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij

QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY

• https://bit.ly/40e91I9

A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). https://t.co/sax8iHuljb https://t.co/71zqAzZViV

• https://bit.ly/3JLShCO

Itaconate - A Potential New Immunosuppressive Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases. https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM

• https://bit.ly/3JKLMQH

Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023

Follow my coverage tomorrow and Sunday! #RNL2023 RheumNow Live ⁦@RheumNow⁩ #RheumTwitter https://t.co/6cZHJxPltA